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Shytaj et al. [1] report that complete
suppression of SIVmac replication can be
achieved in rhesus macaques by a combi-
nation of five antiretroviral (ARV) drugs,
which the authors term ‘‘mega-HAART’’.
This combination consists of the three-
drug nucleoside reverse transcriptase in-
hibitor (tenofovir/emtricitabine) and inte-
grase inhibitor (raltegravir) regimen often
used in treatment studies of simian immu-
nodeficiency virus (SIV)-infected rhesus
macaques, intensified with the protease
inhibitor darunavir (pharmacokinetically
enhanced by ritonavir) and the CCR5
antagonist maraviroc. Achieving complete
suppression of SIVmac in rhesus ma-
caques is an important step in developing
an animal model for HIV-1 cure research
because it parallels the effects of antiret-
roviral therapy in HIV-infected humans.
Without complete suppression, testing of
therapeutic strategies to reduce viral
reservoirs is confounded by ongoing cycles
of viral replication that can replete such
reservoirs.
Over the last two decades, rhesus
macaque models of AIDS have revealed
key aspects of HIV-1 pathogenesis, such as
virus transmission and early events post-
infection, the sites of viral replication and
CD4+ T cell depletion, and virus and cell
turnover [2–8]. These models have also
been instrumental for vaccine research,
allowing the evaluation of increasingly
potent DNA and vector immunogens
and combinations of these vectors in
various prime-boost combinations [9–11].
Macaque models of preexposure prophy-
laxis (PrEP) have also helped elucidate the
ARV exposures and the timing of expo-
sure required to maximize protection from
virus challenge [12].
By contrast, the rhesus macaque/SIV
model has contributed less to the develop-
ment and optimization of ARV therapy
[13]. The main reasons for this include the
natural resistance of SIVs to nonnucleo-
side reverse transcriptase inhibitors
(NNRTIs) [14,15], major differences in
ARV pharmacokinetics between humans
and macaques [13,16], and divergent
interactions of SIVmac and HIV-1 with
host restriction factors [17]. Importantly,
because the pandemic HIV-1 subtypes do
not replicate in monkey species [18],
simian counterparts derived from natural-
ly infected sooty mangabeys, such as
SIVmac/smm, must be used [19]. Al-
though SIVsmm is not completely distinct
from its HIV relatives, being the cause of
the HIV-2 epidemic [20], the differences
in ARV susceptibility and pharmacokinet-
ics have restricted the use of the RM/
SIVmac models for antiretroviral therapy.
Nevertheless, many ARVs are active in
vitro and in vivo against SIVmac [14,21],
and studies of antiretroviral therapy (ART)
in macaques have been reported [21–24].
In most of these studies, however, com-
plete control of viral replication has not
been achieved [14]. In addition to subop-
timal pharmacokinetics, failure to achieve
complete control of viral replication is
likely related to the biology of SIVmac
infection in rhesus macaques. SIVmac is
more virulent than HIV-1 [3]. The set
point of viremia in SIV-infected macaques
is 10- to 100-fold higher than in HIV-1
infection, and progression to AIDS occurs
in 1–2 years and more quickly (,1 year) in
up to 40% of macaques [3,9]. Alternatives
to SIVmac have been reported, most
notably the use of chimeric HIV-SIV
viruses (called simian-human immunode-
ficiency viruses or SHIVs) in which
SIVmac reverse transcriptase (RT) is
replaced by HIV-1 RT (RT-SHIVs) [25–
27]. RT-SHIVs have the advantage of
being susceptible to both nucleoside and
non-nucleoside RT inhibitors similar to
HIV-1. These chimeric viruses also have
limitations, most notably that, similar to
the parental virus, RT-SHIVmac is diffi-
cult to suppress with the same three-drug
combination (tenofovir/emtricitabine/efa-
virenz) that is most commonly used in
humans [25]. As an alternative approach,
RT-SHIVmne was constructed using the
SIVmne isolate from pigtailed macaques
and is used to infect this species. RT-
SHIVmne is less virulent than SIVmac
and not infrequently can be controlled by
the host without intervention. Even so,
ART with tenofovir/emtricitabline/efavir-
enz failed to completely control RT-
SHIVmne replication in chronically in-
fected pigtailed macaques, as evidenced by
both persistent viral replication and se-
quence evolution under treatment [26,27].
The recent report that one patient (‘‘the
Berlin patient’’) was cured of HIV infec-
tion [28] has renewed enthusiasm for a
‘‘cure research’’ aimed at understanding
the mechanisms of HIV-1 persistence and
developing therapeutic strategies to reduce
and ultimately eliminate viral reservoirs.
Limitations of human clinical studies,
especially invasive sampling of multiple
reservoir sites, make it imperative to
develop analogous and tractable animal
models for cure research. Several groups
are trying to achieve this goal by (i) ARV
intensification in SIVmac-infected rhesus
macaques to completely suppress viral
replication, similar to Shytaj et al. [1] (J.
Lifson, unpublished data; P. Luciw, un-
published data), (ii) use of Chinese ma-
caques infected with SIVmac (B. Ling,
unpublished data), in which viral replica-
tion at set point viral replication is lower
than in Indian rhesus macaques [29],
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which have dominated AIDS research,
and (iii) development of an animal model
of functional cure in the absence of ART
[30]. Additionally, humanized mouse
models of HIV-1 infection have been
developed for cure research [31].
How these varied animal models should
be used for cure research is not well
defined. Several different therapies could
have contributed to the cure of the Berlin
patient, including myeloablative chemo-
therapy, total body irradiation, transplan-
tation of allogeneic D32/D32stem cells,
immunosuppressive agents, and graft-ver-
sus-host disease, for which animal models
are impractical [28]. Irrespective of the
mechanisms of the cure, careful charac-
terization of viral reservoirs is the keystone
of cure research. Such studies should
involve invasive sampling and detailed
description of the sites of virus persistence
on completely suppressive ART, as well as
identifying the source of viral rebound
after cessation of ART. New therapeutic
strategies can then be tested, including
selective activators of viral expression,
reversal of immune exhaustion, and en-
hancement of viral specific immune re-
sponses, with careful quantification of
effects on viral reservoirs in different
anatomic sites, including the brain. For
obvious ethical reasons, such studies can-
not be performed in humans. In addition,
because the time of infection and the virus
inocula can be controlled in animal
models, studies can be performed to assess
the optimal timing of cure interventions as
has been reported for PrEP [12]. In
addition, animal models for cure research
can establish ‘‘proof of concept’’ for the
many new therapeutic strategies emerging
in the field before testing in humans. It is
essential, however, that the therapeutic
benefits observed in animal models are
validated in human studies (and vice
versa), and that the cause of discrepancies
be elucidated. Because none of the current
animal models perfectly reproduce HIV-1
infection and ART, it is likely that several
different models will be needed to under-
stand virus persistence, latency, reactiva-
tion, and eradication.
As such, establishing a nonhuman
primate model of complete viral suppres-
sion as reported by Shytaj et al. [1] is a
step forward for cure research. One may
argue that achieving complete control of
viral replication is just a baby step towards
the overall goal of virus eradication and
that much more needs to be accomplished
with regard to developing more sensitive
virological assays [32], small molecules to
activate latent virus [33–36], and biologics
to clear viral reservoirs [37,38]. Neverthe-
less, approaches like that of Shytaj et al.
[1] indicate that control of viral replication
is possible in macaques if drug potent,
multidrug combinations are employed and
that nonhuman primate models for cure
research are here to stay.
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